

SIERRA LEONE PENTAVALENT VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1.	Country: Sierra Leone			
2.	Grant Number: 0815-SLE-04c-X			
3.	Date of Decision Letter: 12 December 2014			
4.	Date of the Partnership Framework Agreement: 31 October 2013			
5.	Programme Title: NVS, Pentavalent Routine			
6.	Vaccine type: Pentavalent			
7.	Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8.	Programme Duration ¹ : 2007 - 2015			
9.	Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
		2007-2014	2015	Total ²
	Programme Budget (US\$)	US\$14,617,934 ³	US\$1,218,500	US\$15,836,434
10.	Vaccine Introduction Grant: Not applicable			
11.	Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement): ⁴ The Annual Amount for 2015 has been amended.			
	Type of supplies to be purchased with Gavi funds in each year	2007-2014	2015	
	Number of Pentavalent vaccines doses		596,000	
	Number of AD syringes		691,700	
	Number of safety boxes		7,625	
	Annual Amounts (US\$)	US\$14,617,934 ⁵	US\$1,218,500	

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

12. Procurement agency: UNICEF									
13. Self-procurement: Not applicable									
<p>14. Co-financing obligations: Reference code: 0815-SLE-04c-X-C. According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2015</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>67,500</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$128,340</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$133,000</td> </tr> </tbody> </table>		Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	67,500	Value of vaccine doses (US\$)	US\$128,340	Total Co-Financing Payments (US\$) (including freight)	US\$133,000
Type of supplies to be purchased with Country funds in each year	2015								
Number of vaccine doses	67,500								
Value of vaccine doses (US\$)	US\$128,340								
Total Co-Financing Payments (US\$) (including freight)	US\$133,000								
15. Operational support for campaigns: Not applicable									
16. Additional documents to be delivered for future disbursements:									
<table border="1"> <thead> <tr> <th>Reports, documents and other deliverables</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>Annual Progress Report or its equivalent.</td> <td>At a date agreed with Gavi Secretariat.</td> </tr> </tbody> </table>		Reports, documents and other deliverables	Due dates	Annual Progress Report or its equivalent.	At a date agreed with Gavi Secretariat.				
Reports, documents and other deliverables	Due dates								
Annual Progress Report or its equivalent.	At a date agreed with Gavi Secretariat.								
<p>17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*: Country is required to finalise IHPAU arrangements before Gavi will make cash disbursements directly to country. All relevant documentation and confirmation of bank account details must be submitted to Gavi prior to any grant disbursement.</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>									
18. Other conditions: Not applicable									

On behalf of the GAVI Alliance



Hind Khatib-Othman
Managing Director, Country Programmes

12 December 2014

SIERRA LEONE PNEUMOCOCCAL VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone			
2. Grant Number: 1215-SLE-12c-X			
3. Date of Decision Letter: 12 December 2014			
4. Date of the Partnership Framework Agreement: 31 October 2013			
5. Programme Title: NVS, Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID			
8. Programme Duration¹: 2010 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2010-2014	2015	Total ²
Programme Budget (US\$)	US\$16,579,752 ³	US\$2,261,000	US\$18,840,752
10. Vaccine Introduction Grant: Not applicable			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴ The Annual Amount for 2015 has been amended.			
Type of supplies to be purchased with Gavi funds in each year	2010-2014	2015	
Number of Pneumococcal vaccines doses		534,600	
Number of AD syringes		592,100	
Number of safety boxes		6,525	
Annual Amounts (US\$)	US\$16,579,752 ⁵	US\$2,261,000	
12. Procurement agency: UNICEF			
13. Self-procurement: Not applicable			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 1215-SLE-12c-X-C. According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	32,400
Value of vaccine doses (US\$)	US\$107,055
Total Co-Financing Payments (US\$) (including freight)	US\$113,500

15. Operational support for campaigns: Not applicable

	2015
Grant amount (US\$)	US\$


16. Additional documents to be delivered for future disbursements:

Reports, documents and other deliverables	Due dates
Annual Progress Report	At a date agreed with Gavi Secretariat.

17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*:
Country is required to finalise IHPAU arrangements before Gavi will make cash disbursements directly to country. All relevant documentation and confirmation of bank account details must be submitted to Gavi prior to any cash disbursements.
**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: Not applicable

On behalf of the GAVI Alliance



Hind Khatib-Othman
Managing Director, Country Programmes

12 December 2014

SIERRA LEONE ROTAVIRUS VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone									
2. Grant Number: 1215-SLE-13b-X									
3. Date of Decision Letter: 12 December 2014									
4. Date of the Partnership Framework Agreement: 31 October 2013									
5. Programme Title: NVS, Rotavirus Routine									
6. Vaccine type: Rotavirus									
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule									
8. Programme Duration¹: 2014 - 2015									
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):									
<table border="1"> <thead> <tr> <th></th> <th>2014</th> <th>2015</th> <th>Total²</th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td>US\$1,505,500³</td> <td>US\$628,000</td> <td>US\$2,133,500</td> </tr> </tbody> </table>		2014	2015	Total ²	Programme Budget (US\$)	US\$1,505,500 ³	US\$628,000	US\$2,133,500	
	2014	2015	Total ²						
Programme Budget (US\$)	US\$1,505,500 ³	US\$628,000	US\$2,133,500						
10. Vaccine Introduction Grant: Not applicable									
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴ The Annual Amount for 2015 has been amended.									
<table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Gavi funds in each year</th> <th>2014</th> <th>2015</th> </tr> </thead> <tbody> <tr> <td>Number of Rotavirus vaccines doses</td> <td></td> <td>235,500</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td>US\$1,505,500⁵</td> <td>US\$628,000</td> </tr> </tbody> </table>	Type of supplies to be purchased with Gavi funds in each year	2014	2015	Number of Rotavirus vaccines doses		235,500	Annual Amounts (US\$)	US\$1,505,500 ⁵	US\$628,000
Type of supplies to be purchased with Gavi funds in each year	2014	2015							
Number of Rotavirus vaccines doses		235,500							
Annual Amounts (US\$)	US\$1,505,500 ⁵	US\$628,000							
12. Procurement agency: UNICEF									

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

13. Self-procurement: Not applicable									
<p>14. Co-financing obligations: Reference code: 1215-SLE-13b-X-C According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2015</td> </tr> <tr> <td>Number of vaccine doses</td> <td>19,500</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$49,084</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$51,000</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	19,500	Value of vaccine doses (US\$)	US\$49,084	Total Co-Financing Payments (US\$) (including freight)	US\$51,000
Type of supplies to be purchased with Country funds in each year	2015								
Number of vaccine doses	19,500								
Value of vaccine doses (US\$)	US\$49,084								
Total Co-Financing Payments (US\$) (including freight)	US\$51,000								
15. Operational support for campaigns: Not applicable									
<p>16. Additional documents to be delivered for future disbursements:</p> <table border="1"> <thead> <tr> <th>Reports, documents and other deliverables</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>Annual Progress Report or its equivalent.</td> <td>At a date agreed with Gavi Secretariat.</td> </tr> </tbody> </table>		Reports, documents and other deliverables	Due dates	Annual Progress Report or its equivalent.	At a date agreed with Gavi Secretariat.				
Reports, documents and other deliverables	Due dates								
Annual Progress Report or its equivalent.	At a date agreed with Gavi Secretariat.								
<p>17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*: Country is required to finalise IHPAU arrangements before Gavi will make cash disbursements directly to country. All relevant documentation and confirmation of bank account details must be submitted to Gavi prior to any cash disbursement.</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>									
18. Other conditions: Not applicable									

On behalf of the GAVI Alliance



Hind Khatib-Othman
Managing Director, Country Programmes

12 December 2014

SIERRA LEONE YELLOW FEVER VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone																		
2. Grant Number: 0715-SLE-06b-X																		
3. Date of Decision Letter: 12 December 2014																		
4. Date of the Partnership Framework Agreement: 31 October 2013																		
5. Programme Title: NVS, Yellow Fever Routine																		
6. Vaccine type: Yellow Fever																		
7. Requested product presentation and formulation of vaccine: Yellow Fever, 10 dose(s) per vial, LYOPHILISED																		
8. Programme Duration¹: 2003 - 2015																		
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):																		
<table border="1"> <thead> <tr> <th></th> <th>2003-2014</th> <th>2015</th> <th>Total²</th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td>US\$2,087,090³</td> <td>US\$200,000</td> <td>US\$2,287,090</td> </tr> </tbody> </table>		2003-2014	2015	Total ²	Programme Budget (US\$)	US\$2,087,090 ³	US\$200,000	US\$2,287,090										
	2003-2014	2015	Total ²															
Programme Budget (US\$)	US\$2,087,090 ³	US\$200,000	US\$2,287,090															
10. Vaccine Introduction Grant: Not applicable																		
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴ The Annual Amount for 2015 has been amended.																		
<table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Gavi funds in each year</th> <th>2003-2014</th> <th>2015</th> </tr> </thead> <tbody> <tr> <td>Number of Yellow Fever vaccines doses</td> <td></td> <td>174,700</td> </tr> <tr> <td>Number of AD syringes</td> <td></td> <td>210,300</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> <td>23,700</td> </tr> <tr> <td>Number of safety boxes</td> <td></td> <td>2,575</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td>US\$2,087,090⁵</td> <td>US\$200,000</td> </tr> </tbody> </table>	Type of supplies to be purchased with Gavi funds in each year	2003-2014	2015	Number of Yellow Fever vaccines doses		174,700	Number of AD syringes		210,300	Number of re-constitution syringes		23,700	Number of safety boxes		2,575	Annual Amounts (US\$)	US\$2,087,090 ⁵	US\$200,000
Type of supplies to be purchased with Gavi funds in each year	2003-2014	2015																
Number of Yellow Fever vaccines doses		174,700																
Number of AD syringes		210,300																
Number of re-constitution syringes		23,700																
Number of safety boxes		2,575																
Annual Amounts (US\$)	US\$2,087,090 ⁵	US\$200,000																
12. Procurement agency: UNICEF																		
13. Self-procurement: Not applicable.																		

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 0715-SLE-06b-X-C. According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	40,300
Value of vaccine doses (US\$)	US\$40,273
Total Co-Financing Payments (US\$) (including freight)	US\$43,000

15. Operational support for campaigns: Not applicable

16. Additional documents to be delivered for future disbursements:

Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent.	At a date agreed with Gavi Secretariat.

17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*:
Country is required to finalise IHPAU arrangements before Gavi will make cash disbursements directly to country. All relevant documentation and confirmation of bank account details must be submitted to Gavi prior to any cash disbursement.
**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.

On behalf of the GAVI Alliance



Hind Khatib-Othman
Managing Director, Country Programmes

12 December 2014